Actuate Therapeutics, Inc. has entered into a securities purchase agreement for a private placement with institutional and accredited investors, expected to close by June 30, 2025. The company anticipates gross proceeds of approximately $4.7 million, which will be used for working capital and general corporate purposes. As part of the agreement, Actuate will issue 666,497 shares of common stock at $7.00 per share and warrants to purchase an equivalent number of shares at the same price. The warrants will be exercisable on a cash-only basis, expiring 20 days after certain FDA-related milestones are reached. Additionally, Actuate has committed to registering the resale of these securities with the SEC, with specific deadlines for filing and effectiveness. Bios 2024 Co-Invest, LP, a significant shareholder, will participate in the private placement, acquiring 71,428 shares and warrants for approximately $500,000.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.